Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novocure Limited (NASDAQ: NVCR) SEC filings page on Stock Titan provides access to the company’s official disclosures as a registrant under U.S. securities laws. Novocure is incorporated in Jersey and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37565. These filings document material events, financial performance and regulatory updates related to its Tumor Treating Fields (TTFields) oncology business.
Among the key documents available are Form 8-K current reports, which Novocure uses to announce items such as quarterly financial results, clinical trial decisions and regulatory milestones. Recent 8-K filings reference press releases on net revenues, active patient counts on TTFields therapy, and the termination of the LUNAR-4 trial, as well as regulatory approvals like Japan’s Ministry of Health, Labour and Welfare decision on Optune Lua for certain NSCLC patients.
Investors and researchers can also use this page to monitor periodic reports such as annual and quarterly filings when available, which typically include consolidated financial statements, details on research, development and clinical study expenses, and discussions of sales, marketing and general and administrative costs. These documents provide structured insight into Novocure’s TTFields-based product portfolio, including Optune Gio and Optune Lua, and the company’s spending on clinical and regulatory programs in glioblastoma, non-small cell lung cancer, mesothelioma and pancreatic cancer.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand changes in revenue, operating expenses, cash position and key clinical or regulatory disclosures. Users can also review insider and management-related filings such as Forms 3, 4 and 5 when available, to track equity transactions by directors and officers.
With real-time updates from EDGAR and AI-assisted explanations, this page serves as a focused resource for analyzing Novocure’s regulatory record, financial condition and material events that shape its TTFields oncology platform.
NovoCure Ltd Chief Operating Officer Paravasthu Mukund reported mandated tax-related share sales. He sold a total of 1,963 ordinary shares in open-market transactions, including 1,555 shares on February 27, 2026 at a weighted average price of $13.6638 and 408 shares on March 2, 2026 at a weighted average price of $13.4930.
The filing notes these shares were sold to cover tax withholding obligations arising from vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the sales were required by a “sell to cover” arrangement rather than being discretionary trades. After these transactions, Mukund directly owns 76,343 ordinary shares.
NovoCure Ltd insider Nicolas Leupin, the company’s former Chief Medical Officer, reported an open-market sale of 1,029 ordinary shares on February 27, 2026 at a weighted average price of $13.6638 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under NovoCure’s equity incentive plans, as required by the award agreement. After this tax-related, non-discretionary “sell to cover” transaction, Leupin continued to hold 104,079 ordinary shares directly.
NovoCure Ltd’s Chief Executive Officer Leonard Frank X reported a mix of share awards and sales. On February 28, 2026, performance-based restricted stock units vested into 18,621 ordinary shares at no cost to him. Around this vesting, he executed open-market sales totaling 16,966 ordinary shares on February 27 and March 2, 2026 at weighted average prices of about $13.66 and $13.49 per share. A footnote explains that these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations under the company’s equity plans, rather than discretionary trades. Following these transactions, he directly holds 349,400 ordinary shares of NovoCure.
NovoCure Ltd’s former Chief Executive Officer Ashley Cordova reported a mix of equity award activity and related tax withholding. On February 28, 2026, Cordova acquired 23,818 Ordinary Shares at $0.00 per share from the vesting of performance-based restricted stock units.
On February 27 and March 2, 2026, Cordova disposed of Ordinary Shares in several tax-withholding dispositions tied to restricted stock unit vesting. These non-discretionary transactions withheld 11,541 shares at $13.75, and 2,410 and 7,228 shares at $13.67, to cover tax obligations as approved under Rules 16b-3(e) and 16b-3(d)(1).
NovoCure Ltd reported an insider equity award for its General Counsel, Ben Arye Barak. He acquired 17,755 ordinary shares on February 28, 2026 at a stated price of $0.00 per share, described as the vesting of performance-based restricted stock units.
Following this grant/vesting, Barak’s direct holdings increased to 192,328 ordinary shares. This transaction reflects stock-based compensation rather than an open-market purchase or sale.
Morgan Stanley Smith Barney LLC reported a Form 144 disclosing an insider sale: Francis Leonard sold 9,734 common shares of NVCR on 02/27/2026 for $133,003.43. The filing also lists 5,507 performance shares and 1,725 restricted stock with trade dates 02/28/2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice reporting proposed sales of company equity. The filing lists 818 Restricted Stock and 2,454 Performance Shares dated 02/28/2026. It also reports sales of 7,461 common shares on 02/27/2026 for $103,256.51.
NovoCure Limited is a global oncology company focused on Tumor Treating Fields (TTFields), a medical device–delivered electric field therapy designed to disrupt cancer cell division. Its main commercial products are Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer.
The company generates most revenue from Optune Gio use in the U.S., Germany, France and Japan, and is pursuing broader reimbursement and geographic expansion. NovoCure highlights positive late‑stage data, including the METIS brain metastases trial, and is advancing multiple Phase 2 and 3 studies in GBM, NSCLC and pancreatic cancer while emphasizing extensive regulatory, manufacturing, reimbursement and competition risks.